NCI Data Catalog

BRD is a free, publicly accessible literature database that contains peer-reviewed primary and review articles and Standard Operation Procedures (SOPs) in the field of human biospecimen science.
Each literature curation captures the following relevant parameters:

• Biospecimen investigated, analyte(s) of interest, and technology platforms employed
• Pre-analytical factors investigated
• An original summary of relevant results

You can find SOPs in a system with Biospecimen Evidence Based Practices (BEBP).

CDAS is a submission and tracking system for the National Lung Screening Trial (NLST) data and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial data.
The data includes a:

• summary of the trial.
• description of the data collected.
• searchable list of research projects and publications.

This centralized, controlled-access database is a repository of de-identified, patient level data from phase III clinical trials conducted by NCI’s National Clinical Trials Network (NCTN), (NCI’s Community Oncology Research Program (NCORP), and the Canadian Cancer Trials Group (CCTG).

After approval of a signed Data Use Agreement (DUA), you can download patient level clinical data sets and their associated data dictionaries.

The Personalized Cancer Therapy website is a tool for physicians and patients to assess potential therapy options based on specific tumor biomarkers. The focus is on the potential therapy strategies for tumors harboring certain genomic alterations regardless of disease site.

The available data includes:

• study association of a detected genomic alteration with tumor development and growth.
• association of genomic alteration to increased or decreased response to therapy.
• availability of relevant Food and Drug Administration (FDA) approved therapies or investigational agents in clinical trials.

You can find/analyze NCI-60 in CellMiner. NCI’s Developmental Therapeutics Program used this panel of 60 diverse human cancer cell lines to screen over 100,000 chemical compounds and natural products since 1990.

You can download gene expression data files from NCI-hosted FTP sites:

• Gene Expression 1
• Gene Expression 2

SEER collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 30 percent of the U.S. population.

The SEER database includes incidence and population data associated by:

• Age
• Sex
• Race
• Year of diagnosis
• Geographic areas

You can access SEER statistics and the Division of Cancer Control and Population Sciences (DCCPS) data resources on the DCCPS website.

The SEER-CAHPS data resource links data from NCI’s Surveillance, Epidemiology and End Results (SEER) cancer registry program, the Centers for Medicare & Medicaid Services’ (CMS) Medicare Consumer Assessment of Healthcare Providers and Systems (CAHPS®) patient experience surveys, and longitudinal Medicare claims data on utilization and costs of care for Fee-For-Service beneficiaries.

You can request data access by emailing the required documents to NCISEERCAHPS@nih.gov.

The SEER-MHOS database links data from NCI’s Surveillance, Epidemiology and End Results (SEER) cancer registry program and the Centers for Medicare & Medicaid Services (CMS) Medicare Health Outcomes Survey (MHOS) that provides information about the health-related quality of life (HRQOL) of Medicare Advantage Organization (MAO) enrollees. NCI and CMS sponsor the database.

You can email the required documents to SEER-MHOS@hcqis.org to request access to the data.

GDC provides the cancer research community with a unified data repository that enables data sharing across cancer genomic studies in support of precision medicine. The GDC supports several cancer genome programs at the NCI Center for Cancer Genomics (CCG) including:

• The Cancer Genome Atlas (TCGA)
• Therapeutically Applicable Research to Generate Effective Treatments (TARGET)
• The Cancer Genome Characterization Initiative (CGCI)

CGCI researchers develop and apply advanced sequencing and other genome-based methods to identify novel genetic abnormalities in both adult and pediatric cancers. The genetic profiles inform better cancer diagnosis and treatment.

• You can access CGCI data through the project data matrix.

The I-SPY 1 TRIAL sought to identify indicators of response to neoadjuvant chemotherapy that predict survival in women with high-risk breast cancer.

• You can download gene expression data files from an NCI-hosted FTP site.

Researchers have measured thousands of molecular targets in the NCI panel of 60 human tumor cell lines. You can search for or browse through a list of targets.
Measurements include:

• Protein levels
• RNA measurements
• Mutation status
• Enzyme activity levels

NCI Brain Neoplasia Data (Rembrandt Database) integrates clinical and functional genomics data from clinical trials involving brain tumor patients and provides the ability to perform ad hoc querying, reporting and analysis across multiple data domains, including gene expression, gene copy number and clinical data.

• You can download gene expression files from a NCI-hosted FTP site.

TARGET applies a comprehensive genomic approach to determine molecular changes that drive childhood cancers. The goal is to facilitate the discovery of therapeutic targets for childhood cancers and catalyze the translation of these discoveries into clinical applications.

The TARGET data matrix includes:

• genomic data.
• clinical information that doesn’t identify patients.

The Cancer Genome Atlas (TCGA) is a comprehensive effort to accelerate the understanding of the molecular basis of cancer through the application of genome analysis technologies. Through the TCGA Data Portal, you can search, download, and analyze data from over 30 different types of cancer. It contains:

• clinical information that doesn’t identify patients.
• genomic characterization data.
• high level sequence analysis of the tumor genomes.

A large, training, testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas. The study looked at whether microarray measurements of gene expression either alone or combined with basic clinical covariates (stage, age, sex) predicted overall survival in lung cancer subjects.

• The DC Lung Study data set is available for analysis in Gene Expression Omnibus (GEO).

IDC provides the cancer research community with a cloud-based repository of cancer imaging data, image annotations, and analysis results. IDC uses the Digital Imaging and Communication in Medicine (DICOM) standard to harmonize the data. You can find imaging data from the following NIH/NCI projects:

• The Cancer Genome Atlas (TCGA)
• Lung Imaging Database Consortium (LIDC)
• Clinical Proteomics Tumor Analysis Consortium (CPTAC)
• Human Tumor Atlas Network (HTAN)
• NCI Quantitative Imaging Network (QIN)
• National Library of Medicine Visible Human Project (VHP)

TCIA is a curated archive of medical images that you can download. It includes data from the National Lung Screening Trial (NLST) and many subjects from The Cancer Genome Atlas (TCGA). You can find data divided into collections and grouped by common cancer types or research aims. You can also search these collections by modality, anatomic location, or various acquisition parameters. You can access pathology imaging, patient demographics/outcomes, expert-derived segmentations/annotations, genomics, and other available supporting data.

July 2024 Update: New data includes:

• renal cell carcinomas (RCCs) from NCI’s CPTAC multi-omic analysis of clear and non-clear RCC cases.
• head and neck cancers treated with identical prescriptions using intensity modulated radiation therapy.

Visit the TCIA website for full details.

caNanoLab includes over 1,000 curated nanomaterials relevant in cancer with detailed characterizations and associated nanotechnology protocols and publications

• You can perform web-based queries and download reports for re-use and additional analysis.

NDEx allows you to share, store, manipulate and publish biological network information. The project maintains a public NDEx server and is a joint effort of the UC San Diego School of Medicine and the Cytoscape Consortium.

• Access published networks aggregated from several pathway and interaction databases.
• Create your own networks to use, share, or publish.

The CCDI CCDC is an inventory of pediatric oncology data resources. This includes childhood cancer repositories, registries, knowledge bases, and catalogs that either manage or refer to data.

June 2024 Update: The Catalog now includes 4 new data sets, in addition to updated counts from CancerModels.org, Patient-Derived Xenograft, and Advanced In Vivo Models data sets. You may also find it easier to search information in the Childhood Cancer and Leukemia International Consortium data set thanks to a reorganization. Visit the catalog website for full details. Visit the catalog website for full details.

CCDI Hub Explore Dashboard: This integrated tool provides you with the search functionality to connect participants with files and samples. It enables you to find data within a single study or across multiple studies, and create synthetic cohorts based on filtered metrics of interest (i.e. demographics, diagnosis, samples).

CCDI Molecular Target Platform (MTP): Use this tool to browse and identify associations between molecular targets, diseases, and drugs specific for childhood cancers.

Childhood Cancer Clinical Data Commons (C3DC): This open access, web application allows you to find harmonized demographic and clinical data, create custom cohorts, and download data for local analysis.

June 2024 Update: This CCDI Hub release includes new and updated data sets, along with enhanced features and improved functionality for the Molecular Characterization Initiative and the Explore Dashboard. Visit the CCDI Hub website for more details.

You can get open access, highly curated, and standardized biospecimen, clinical, and proteomic data from PDS. You can analyze PDC data files using tools found in the CRDC Cloud Resources. Data sets include the following:

• NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC)
• Children’s Brain Tumor Tissue Consortium (CBTTC)
• International Cancer Proteogenomic Consortium (ICPC)

August 2024 Update: PDC released six new studies on non-clear cell renal cell carcinomas, plus a new metabolomics feature that includes mass spectrometry-based CPTAC metabolomic and lipidomic data. Visit the PDC for more details.

CTD² bridges the gap between the enormous volumes of data generated by genomic characterization studies and the ability to use these data for the development of human cancer therapeutics. It specializes in using computational and functional genomic approaches to translate next-generation sequencing data, and data from high-throughput and high content small molecule and genetic screens, into clinical applications. All data generated are open access.

• The CTD² Data Portal consists of raw and analyzed primary data.